These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8503027)

  • 1. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
    Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
    Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D; Spaas P; Specenier P
    Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C; Zhang D; Yu L
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT; McEwan AJ
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.